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Abstract—The recent successful births following live donor
uterus transplantation are proof-of-concept that absolute
uterine factor infertility is a treatable condition which affects
several hundred thousand infertile women world-wide due to
a dysfunctional uterus. This strategy also provides an
alternative to gestational surrogate motherhood which is
not practiced in most countries due to ethical, religious or
legal reasons. The live donor surgery involved in uterus
transplantation takes more than 10 h and is then followed by
years of immunosuppressive medication to prevent uterine
rejection. Immunosuppression is associated with signiﬁcant
adverse side effects, including nephrotoxicity, increased risk
of serious infections, and diabetes. Thus, the development of
alternative approaches to treat absolute uterine factor
infertility would be desirable. This review discusses tissue
engineering principles in general, but also details strategies
on how to create a bioengineered uterus that could be used
for transplantation, without risky donor surgery and any
need for immunosuppression. We discuss scaffolds derived
from decellularized organs/tissues which may be recellular-
ized using various types of autologous somatic/stem cells, in
particular for uterine tissue engineering. It further highlights
the hurdles that lay ahead in developing an alternative to an
allogeneic source for uterus transplantation.
Keywords—Bioengineering, Reproduction, Decellulariza-
tion, Recellularization, Scaffold, Bioreactor, Mesenchymal
stem cells.
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There has been great progress in the clinical ﬁeld of
solid organ transplantation during the last three dec-
ades, in particular since the introduction of cal-
cineurin-inhibiting immunosuppressive drugs to
eﬀectively prevent graft rejection.105 These advance-
ments have assisted clinical innovators to implement
various types of vascularized composite tissue trans-
plantation protocols for non-vital tissue transplanta-
tion such as the hand, forearm and face to enhance
function and quality-of-life.27,33 After more than a
decade of pre-clinical research on small- and large
animal models,12,24,28,34,48,78,79,109–111 our group
obtained enough skills and scientiﬁc evidence to re-
ceive ethical permission to evaluate uterus transplan-
tation (UTx) as a mean to potentially cure absolute
uterine factor infertility (AUFI), a condition of per-
manent infertility that is often associated with sub-
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stantial socio-psychological discomfort.93 AUFI is
caused by congenital or acquired uterine defects such
as after severe intrauterine adhesions or due to partial
uterine malformation, or after hysterectomy (due to
cervical cancer, large leiomyoma or emergency peri-
partum hysterectomy) and affects about 1:500 women
of fertile age.67
Using live donors, our group transplanted nine wo-
men who received a uterus to replace a uterus missing
from birth (Mayer–Rokitansky–Ku¨ster–Hauser-syn-
drome)59 in all cases but one who lost her uterus after a
hysterectomy as a treatment of early stage cervical
cancer. Using standard anti-rejection treatment re-
gimes, seven of these patients had graft survival formore
than a year and were able to start embryo transfer at-
tempts. Up until today, ﬁve healthy babies have been
born and with further ongoing pregnancies.10,11,13,14,70
These successful outcomes demonstrated that UTx of-
fers a curative treatment for infertility caused by AUFI.
Several transplantation centers around the world are in
the process of initiating clinical trials of UTx with some
variations in techniques and donor source (with a de-
ceased- or a live donor). Initial cases have just recently
been reported in the media fromChina, USA and Czech
Republic but have not yet been described in any peer-
reviewed publications.
Allograft tissue is generally used for human trans-
plantation procedures, including in a UTx setting.
However, this is not used without complications. All
transplanted patients face the risks of tissue rejection
and immunosuppressant-related side eﬀects.85 Long-
term graft survival remains a challenge5,9 and patients
become susceptible to infections and certain malig-
nancies, including increased risks of hypertension,
diabetes and accelerated arteriosclerosis.5 High doses
of immunosuppressive drugs following UTx may, at
least temporary, be required to halt progression of
organ rejection. This thwarts potential embryo transfer
attempts, which have been the case for one of the
subjects in our clinical trial. Another issue using tissue
matched donors for transplantation of life-depending
organs is that the number of donors cannot be mat-
ched by the overwhelming number of people waiting
for an organ transplant. A substantial waiting list
mortality is therefore a great concern for patients in
need of a new liver, kidney or a heart for example.83
The development of an alternative donor source, for
example through the progress of an engineered graft-
ing material based on the patient’s own cells to reduce
rejection risks would greatly beneﬁt the transplanta-
tion ﬁeld, including for UTx patients. For these rea-
sons, novel and promising concepts for functional
organ- or tissue replacement have emerged within the
ﬁelds of regenerative medicine and tissue engineering
on a wide range of organs and tissues.6,35,76
Basic Principles of Organ Tissue Engineering
Tissue engineering involves several steps, from the
development of a template (or a scaﬀold), to tissue
reconstruction using various cell sources. The scaﬀold
could be either synthetic or biologically-derived and
should serve to provide structural support for the ad-
ded cells and aid cell proliferation and diﬀerentiation
into an appropriate tissue speciﬁc cell fate. A normal
organ may contain hundreds of millions, or even bil-
lions of cells. Thus the required cells need to be ex-
panded to vast numbers and the engineered construct
needs to be kept in an advanced perfusion bioreactors
in vitro or to be grown ectopically in vivo to be ﬁnalized
prior to its clinical application.
Scaﬀold generation has received much attention in
the past years, in particular biological scaﬀolds since
they, to a greater extent than synthetic scaﬀolds, mimic
the native organ mechanically, geometrically and bio-
logically.76 A biological scaffold can be obtained by a
procedure called decellularization, a process where the
immune provoking cells are removed from a normal
organ which leaves a framework of tissue-speciﬁc
three-dimensional (3D) extra cellular matrix (ECM).6
The ECM provides organ-speciﬁc tissue architecture
with preserved vascular conduits, and contains
important molecules, mainly type I collagen, gly-
cosaminoglycans, ﬁbronectin, laminin, elastin, and a
diverse variety of growth factors with tissue speciﬁc
composition.23 These molecules provide signals for cell
aggregation, adhesion, migration, proliferation, and
differentiation for that speciﬁc tissue.23,47,76,81 The
ECM molecules are highly conserved between species,
and as long as a balanced removal of hydrophilic and
lipophilic antigens occur during decellularization,
without a signiﬁcant loss of ECM morphology, the
decellularized scaffolds can avoid immune rejection in
the recipient.108 These qualities make decellularized
scaffolds interesting constructs for organ reconstruc-
tion studies.
Decellularization can be achieved by exposing the
organ to either detergents, to ionic- or non-ionic
solutions, to physical forces (such as freeze-thawing
and high-/low pressure), or to various enzymatic
treatments. Usually a combination of these methods is
used. However, most are non-selective and will also
damage ECM elements, particularly collagen, gly-
cosaminoglycans, and resident growth factors.36 It is
important to ﬁnd a balance between an aggressive
enough decellularization process that removes the
immunogenic DNA and intracellular components
while maintaining the ECM microenvironment intact,
including patent conduits for the vasculature. With
whole organs, the perfusion of decellularization
chemicals through the vasculature is effective, but tis-
HELLSTRO¨M et al.
sues can also be decellularized by immersing them in
decellularization reagents. It is important to analyze
the DNA content of the scaffolds throughout the
process to make sure that sufﬁcient DNA removal is
accomplished to prevent rejection.23 Furthermore,
washing the scaffold is crucial since remnants of the
decellularization reagents may remain and cause ad-
verse events during the reconstruction phase.
When an acellular scaﬀold has been created it may
be implanted directly in vivo to recruit repopulating
endogenous cells from the host, or (more commonly)
cells can be integrated in the scaffold prior to
implantation in a process generally termed ‘‘recellu-
larization’’. One major challenge in tissue engineering
is to ﬁnd an appropriate cell source for the recellular-
ization of the scaffold. For whole-organ engineering,
an ideal cell type is one that can proliferate and give
rise to all cell types necessary for the particular organ
to be regenerated, including the parenchyma, stroma,
the vasculature, and all other supporting structures.
For these reasons, many types of stem cells and pro-
genitor cells have been evaluated, such as embryonic
stem cells, induced pluripotent stem (IPS) cells, and
various somatic stem cells. To date, embryonic- and
mesenchymal stem cells are the most prevalent cell
types used for recellularization.86 However, it is likely a
mix of cell types that will be required for a successful
reconstruction and future work will also focus on what
sequence the different cell types should be applied in.
A successful recellularization also requires optimal
cell delivery methods and culturing conditions. The
two main methods for cell delivery are either perfusion
of cells through the vasculature, or by repeated injec-
tions of cells into the scaﬀold using a syringe. Perfusion
would be the choice in order to reach the vasculature,
whereas injections of cells target the parenchyma and
stroma more directly. Thus, a combination of the two
has been the approach by many groups, including us
(Figs. 1a and 1b). The culturing conditions also mat-
ters on the recellularization efﬁciency, and one of the
advantages with using decellularized biological tissues
is that the vascular conduits are preserved. This route
is therefore commonly used to cannulate and connect
to various custom made- or commercially available
perfusion bioreactors (Figs. 1c and 1d). Negative
pressure in the culturing chamber may also be used to
mechanically enhance cell migration and seeding efﬁ-
ciencies of decellularized organs.92
Progress in Organ Tissue Engineering Using
Decellularized Matrixes
The ﬁeld of organ tissue engineering is still in its
infancy and many challenges remain before the devel-
opment of complex organs will be established. Modest
steps have been made in small animal organ bioengi-
neering, where rudimentary in vivo function and pa-
tency were observed for a very limited time.73,74,77,92,100
For example, tissue engineered rat livers showed
maintained hepatocyte viability and to some extent
metabolic function by producing liver-speciﬁc proteins
in vitro and in vivo.7,55,100 In vitro results of macro-
scopic contractions and pump function of a decellu-
larized rat heart was also established, describing that
cardiovascular progenitor muscle cells and endothelial
cells could migrate, proliferate and differentiate into
cardiomyocytes, smooth muscle cells and endothelial
cells.74 Furthermore, human umbilical vein endothelial
cells and rat neonatal kidney cells were used to recel-
lularize rat kidney scaffolds that developed into spe-
cialized kidney cells.92
The creation of bioengineered tissue parts is less
complicated than the creation of complete organs and
have in some areas successfully been clinically applied
using biologically- or synthetically derived scaﬀolds; for
example engineered skin-,4,69 bone-94 and heart valve
grafts.50 Researchers have also clinically tested bio-
engineered constructs of ‘‘less complex’’ hollow struc-
tures such as urogenital tissues,3 blood vessels 57,71 and
trachea.39,49,64 Due to raised concerns, a few studies are
currently being re-evaluated by external scientiﬁc- and
ethical organizations.53 Nevertheless, many tissue engi-
neering studies show great promise, evidenced by the
vast number of pre-clinical reports using decellulariza-
tion- and recellularization methods for many different
organs and tissues.16,38,44,46,58,63,95,103
Tissue Engineering the Reproductive Organs
Several sites of tissue engineering of female repro-
ductive organs have been investigated,2,82,89 including
the lower female reproductive tract.25,80,97,98 For fer-
tility aid, ovarian- and follicle-related bioengineering
applications have particularly been explored as means
to cure infertility caused by conventional anti-cancer
treatments.89 Fertility is particularly challenging to
retain in leukemia-treated females where the otherwise
successful method of re-transplanting cryopreserved
ovarian tissue is unsafe due to the risk of reintroducing
malignant cells.30–32 However, there are many pre-
clinical reports describing various successful bioengi-
neered supporting structures for isolated early-stage
follicles which were able to support in vitro follicle
maturation.40,61,62,90,91,101,102,107,112 These are signiﬁ-
cant achievements since the 3D microstructure used to
encapsulate growing follicles in vitro must be plastic
enough to allow a massive exponential growth in vol-
ume (in particular for large mammals) and yet also
provide crucial physical support for oocyte–somatic
cell connections that promote follicular development
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throughout the whole process.89 Collectively, these
studies provide hope to the development of future safe
methods to preserve fertility for leukemia treated
patients.
UTERINE TISSUE ENGINEERING
Engineered 3D uterine tissue culturing systems have
been used for a number of years to perform decidual
diﬀerentiation- and embryo implantation stud-
ies.51,66,88 The majority of published work was focused
on fertility issues, however tissue engineered constructs
were also used as in vitro models to study invasion
mechanisms of endometrial cancer cells8,75 and
epithelial- and stromal cell communication.1 Several
studies used scaffolds derived from collagen.29,60,87,104
For example, Lu et al. created a uterus-like stratiﬁed
construct in vitro by sequentially adding rabbit
myometrial-, endometrial-, and epithelial cells in a
collagen/matrigel mix on top of an agar bed. These
constructs supported mouse embryo development and
maintained their quality better than the control group
(mouse embryos grown in normal cell culture ﬂasks
using the same media).60 In a similar study, the
reconstructed rabbit endometrium was improved when
FIGURE 1. Previously unpublished pictures of a Hematoxylin and Eosin stained section (a), and of a section with green fluo-
rescent protein (GFP) labeled cells (b) from a recellularized whole rat uterus scaffold that was kept for 7 days in vitro after
recellularization with about 300 million rat GFP-labeled bone marrow derived mesenchymal stem cells (MSCs). The scaffold was
generated by a decellularization protocol based on perfusing the ionic detergent sodium deoxycholate and deionized H2O
sequentially for 5 days. After recellularization, the engineered uterus construct was kept submerged in media that circulated in a
closed, homemade, perfusion bioreactor which was maintained in a 37 C humidified chamber supplemented with 5% CO2 (c). Note
the vast cell-free scaffold areas in (a, b), and that cells mainly localized around the outside and on the luminal side of the scaffold
(a), and in isolated pockets within the scaffold (b). (c) Picture of the homemade bioreactor used for the particular experiment shown
in (a, b). Note that this particular system did not provide any extra oxygen supply to the media. We have now invested in a highly
sophisticated perfusion bioreactor system from Hugo Sachs Electronic—Harvard Apparatus GmbH (jacketed psu moist chamber
with tubing heat exchanger type 834/10) which gives us much better conditions for 3D-cell culturing, including temperature
regulation, media oxygenation and pressure measurements (d). All animal experiments were approved by the Animal Ethics
Committee in Gothenburg, Sweden. We are currently optimizing our recellularization techniques using this innovative system
which hopefully also will extend our culturing times and reduce the contamination prevalence which has been a significant
problem. Scale bar 200 lm. i, media cistern; ii, bubble trap; iii, organ perfusion site and reservoir; iv, oxygenator; v, peristaltic
pump (not shown in c); vi, media heat exchanger; vii, pressure measure device.
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using estrogen/progesterone stimulated endometrial
cells.104 Collagen-coated silk scaffolds have been used
to construct human cervix-like tissue in vitro and re-
sults showed that a dynamic cell culturing system with
human cervix cells isolated from the cervical stroma
(mid canal region) signiﬁcantly enhanced the concen-
tration of ECM-related molecules and scaffold stiff-
ness when spinner ﬂasks were used over an extended
time period of eight weeks.45 In another study, bone
marrow derived mesenchymal stem cells (BM-MSCs)
were cultured on collagen scaffolds which were then
tested in vivo to repair a full-thickness uterine wall
injury in a rat model.29 Evaluated at 30- and 90 days
after transplantation, grafts improved the healing
process in the uterine wall by inducing proliferative
abilities of host uterine endometrial- and muscular
cells and facilitated microvasculature regeneration.
Embryo development also took place within the graf-
ted area, although authors do not discuss if the actual
placentation was formed over the grafts (which would
have proved optimal reconstruction and vasculariza-
tion of the engineered tissue).29
An earlier report describes myoﬁbroblast-encapsu-
lated grafts that were created by transplanting boiled
blood cloths molded into tubular shapes (5 9 25 mm
in size) into the peritoneal cavity.18 The peritoneal
cavity was used as a host myoﬁbroblast recruitment
site and as a kind of in vivo bioreactor. Two- to three
weeks after initial surgery, the myoﬁbroblast-encap-
sulated grafts were harvested and the tubular shaped
blood cloths were carefully removed so that the
myoﬁbroblast (now also tubular shaped) tissue could
be isolated. This myoﬁbroblast tissue was then used to
repair an injury in the uterine wall of the same animal.
The grafts subsequently became more uterine-like over
the following twelve weeks. Evident structural com-
plexity was observed, including columnar epithelium,
secretory glands, and muscle bundles which were
organized into two distinct layers, but with some
organizational differences compared to normal uterine
tissue. In the same study, pregnancies that were in-
duced 12 weeks post-transplantation showed that
grafts could physically support a growing uterus up to
embryonic day (E) 20. It is somewhat unclear, but to
our understanding, placentation did not appear to
have happened in the grafted tissue itself, but rather in
other areas of normal uterine tissue within the grafted
horn.18 This study does not only show the regenerative
capacity of the rat uterus, but also describe an inno-
vative technique on how to use the peritoneal cavity of
the host as a bioreactor, which perhaps should be
explored further with other constructs.
In two published review papers, a uterine tissue
transplantation study has been reported using the
rabbit model.2,82 Pre-conﬁgured uterine-shaped
biodegradable polymer scaffolds seeded with autolo-
gous uterine smooth muscle cells and epithelial cells
were used to construct bioengineered uterine tissue for
a ‘‘subtotal uterine tissue replacement’’ in the corre-
sponding autologous animal. Based on unpublished
results from immunohistochemistry, western blot and
biomechanical analyzes using organ bath assays of the
grafts, they reported normal uterine tissue components
with functional characteristics similar to those of
normal uterine tissue.82
To our knowledge, it is not until recently that
uterine bioengineering studies have investigated the use
of decellularized material as scaﬀolds to reconstruct
uterine tissues. Pregnant rat- and human myometrium
specimen were decellularized using an ethanol/water/
trypsin decellularization process, which initially was
optimized for large arteries.113 These scaffolds were
then recellularized with various human and rat myo-
cyte cell lines to be evaluated in vitro. Interestingly, the
human cells adapted better to the decellularized rat
scaffolds. These constructs were cultured for up to
51 days in vitro which gave the cells enough time to
form multicellular layers on the scaffold surface and
clusters of cells within the depths of the rat scaffold.
These constructs showed some contractility in an or-
gan bath, indicating elementary uterus phenotype-like
functionality.113 However, no repopulation of the
vascular conduits was observed which may have af-
fected the cell homeostasis deeper in the tissue layers.
Santoso et al. also investigated decellularized uterine
tissue segments.84 They compared three different
decellularization methods for full-thickness rat uterine
segments, using protocols based on (1) sodium dodecyl
sulfate (SDS), (2) Triton-X100, and (3) high hydro-
static pressure (HHP). After detailed analysis, the au-
thors concluded that SDS and HHP were more
effective to obtain decellularization than Triton-X100.
When cell-free SDS- and HHP-derived scaffold seg-
ments were transplanted to repair a defect uterine wall
and analyzed four weeks later, it was evident that both
scaffold types supported local recruitment of host
uterine cells which were positive for estrogen receptor
markers. Pregnancy tests made on the operated rats,
also suggested that the constructs gave some level of
structural support during fetal development.84 In a
recent study, a similar experimental approach was used
in the mouse model where cell-free decellularized
mouse uterus segments were transplanted to ovariec-
tomized mice or to Stat3 conditional knockout mice.43
The results showed that the spontaneous host uterus
regeneration process was independent of ovarian hor-
mones but highlighted a key role for Stat3 in the
regeneration process. Collectively, these studies pro-
vide encouraging results for various bioengineering
strategies for partial uterine repair which is clinically
Uterine Tissue Engineering
relevant in a situation to cover partial uterine defects
caused for example by resection of placental tumors,
extensive myomectomy or adenomyomectomy. A tis-
sue engineered uterine patch may in these cases be used
to increase the strength of the uterine wall in a future
situation of pregnancy.
However, concerning whole-uterus bioengineering
applications, larger constructs with an appropriate
vasculature that can be anastomosed to the host vas-
culature will be necessary. For these reasons, and in
line with what was developed for other whole
organs,73,74,77,92,100 we and one other group evaluated
different strategies to decellularize whole rat uterus.
The rat uterus was isolated with an intact vascular tree
(from the aorta to vena cava) from a donor rat so that
a whole uterus scaffold could be obtained by decellu-
larization, which then enable recellularization and
transplantation with vascular anastomoses.41,68 Miya-
zaki and Maruyama used an SDS-based decellular-
ization protocol originally optimized for the rat
liver.100 At the same time, we developed three different
decellularization protocols; two protocols were based
on a combination of Triton-X100 and dimethyl sul-
foxide (DMSO), where one protocol was buffered in
phosphate buffered saline (PBS) for the duration of the
procedure, while the other was non-buffered (de-ion-
ized H2O).
41 Our third protocol was based on an ionic
detergent called sodium deoxycholate (SDC).41 For all
three protocols, the detergents and ionic solutions were
alternately perfused through the rat uterus via the
vascular system for a total of 5 days. During this
process, the cell membranes were targeted by the
detergents, while the osmotic alternations assisted cell
lysis. DNA and other cell remnants where subse-
quently washed away.41 Together, our two separate
studies provide an excellent platform on to which novel
whole-uterus tissue engineering experiments can be
developed from. However, the treatment differences
during scaffold generation changes the physical,
mechanical and biomolecular properties of the uterine
scaffolds, which potentially impact their functionality.
Thus, before progressing further on whole-uterus bio-
engineering applications, or to larger animal models,
we should try to establish which scaffold design is the
most suitable for the cellular reconstruction and the
successive in vivo applications. For these reasons,
Miyazaki and Maruyama and Hellstro¨m et al. per-
formed similar patch transplantation studies as to
what Ding et al. and Santoso et al. did.29,42,68,84
Miyazaki and Maruyama preconditioned their
SDS-derived whole-uterine scaffolds with collagen,
which were then recellularized by multiple injections
with a total of about eighty million cells per scaffold
from a cell mix of neonatal- and adult uterine cells and
BM-MSCs (with a ratio of about 51:27:1, respectively).
Ten days after recellularization and culture in a per-
fusion bioreactor, segments were cut out (15 9 5 mm)
from the recellularized whole-uterus scaffold and
transplanted to replace a full-thickness uterine wall
segment of the same size by continuous 6-0 prolene
sutures. Twenty-eight days following engraftment,
immunohistochemistry showed a large number of cells
positive for vimentin (stromal cells), cytokeratin (ep-
ithelial cells) and smooth muscle actin (myometrium).
Pregnancies were achieved and fetal weights were
normal in the operated horns, but the total number of
fetuses was signiﬁcantly reduced compared to normal
pregnant animals and no placentation had formed over
the graft. Perhaps these results could have been im-
proved further if the pregnancy was induced at a later
time point after surgery. Indeed the cell quantity and
organization were improved ninety days following
engraftment.68
In collaboration with Dr. Miyazaki and Dr. Mar-
uyama, we recellularized segments (20 9 5 mm) of
decellularized uterus tissue by injecting about 7 million
GFP-labeled BM-MSCs (GFP-BM-MSCs) and adult
primary uterine cells (ratio of 150:1, respectively).
Three days after recellularization, the constructs were
cut in half so that one half could be analyzed and the
other half transplanted to repair a full-thickness uter-
ine wall defect (10 9 5 mm).42 Sections of the con-
structs analyzed histologically prior to transplantation
showed that very few cells were dispersed into the
deeper layers of the scaffolds. Except for some cell
clusters in isolated pockets within the scaffolds, the
cells generally remained on the surfaces of the scaf-
fold.42 Since very few cells were GFP negative, we used
ﬂuorescence, confocal microscopy and automated
software to quantify the cell conﬂuency on the scaffold
surfaces. It turned out that the scaffolds produced with
the mild Triton-X100/DMSO treatment were better at
supporting the recellularized cells compared to
SDC-derived scaffolds, in particular using the buffered
protocol.42 The buffered decellularization protocol
generated uterus scaffolds with signiﬁcantly higher
amounts of sulfated glycosaminoglycans (sGAGs; 2.8–
3.7 times higher compared to the non-buffered proto-
cols) which may have led to the improved recellular-
ization.41 Using proteomics, we also identiﬁed higher
levels of certain collagens and proteoglycans (i.e.
biglycan, decorin, lumican) and a basal lamina-related
protein (nidogen-2) in the Triton-X100/DMSO-gener-
ated scaffolds.41 Scaffold porosity and stiffness also
play an important role in how stem cells
behave.54,96,106 Our SDC-derived scaffolds were 1.5–
1.7 times stiffer and more porous than our Triton-
X100/DMSO-derived scaffolds which showed a very
ﬁber-rich, but compact substrate.41 It can be specu-
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































important role in the recelluarization outcomes.
However, in vitro migration and proliferation were
generally poor in all scaffolds,42 thus culturing condi-
tions (and perhaps scaffold generation) need further
optimization (Table 1).
The recellularized triton-X100/DMSO-derived
scaﬀolds also worked better in vivo compared to the
SDC-derived constructs; grafts showed a higher degree
of homing affect and supported a spontaneous host
cell inﬁltration and organization better. As evidenced
by immunohistochemistry and qPCR, all cells used in
the recellularization process were replaced by inﬁl-
trating host cells in all constructs. However, the GPF-
MSCs contributed to the spontaneous host cell
reconstruction of the grafted tissue since we noticed
that cell free, acellular, scaffolds had completely de-
graded 3 months after transplantation in vivo.42 We
obtained similar numbers of fetuses in the operated
horns compared to the non-operated horn when using
constructs derived from the Triton-X100/DMSO-pro-
duced scaffolds. To our knowledge, these pregnancy
results are better than other published uterine tissue
engineering studies. We considered it important to
analyze the construct in detail prior to transplantation,
which therefore reduced our grafting size material to
become 5 mm smaller in size than that of other studies,
and this fact may have inﬂuenced our in vivo results.
Consequently the results are not easily comparable to
other studies using larger grafts. Other differences
between the studies include the various time points
when pregnancy was induced. For example, we waited
42 days after transplantation (6 weeks), Miyazaki and
Mauyama waited 28 days (4 weeks), Ding et al. waited
90 days and Santoso et al. waited 30 days.29,42,68,84
Naturally this has an inﬂuence on the fertility out-
comes in the operated horns since construct maturity
generally seem to improve over time after transplan-
tation. Other protocol- and technical variations
between research groups make it difﬁcult to directly
compare construct functionality based solely on fetal
numbers. In our latest study, fetal development oc-
curred in the grafted area in two animals in both Tri-
ton-X100/DMSO groups, showing that the uterine
wall containing the graft was strong enough to support
a near full-term pregnancy (E16–E20).42 However, we
also did not see any placentation formed directly over
the engineered graft itself. The reason behind this is
unclear; we speculate that this may be due to an
insufﬁcient blood supply to the graft since the trans-
plantation procedure does not allow for any vascular
anastomoses. Nevertheless, an insufﬁcient cell number,
tissue organization and/or poor epithelium recon-
struction may also be accountable. Many areas of the
grafts showed near-uterus like morphology with well-
developed myometrial-like features and a uniformed
and lined epithelial layer. However, we also noticed a
possible immune cell inﬁltration, granulation forma-
tion and angiogenesis to other areas of the grafts.42 It
is unclear whether this response was caused by the
scaffold, the GFP-labeled cells, or the fact that we used
an outbred rat strain for the experiment. We also do
not know if these events are detrimental or beneﬁcial
since immune system activation can favor tissue
regeneration under particular circumstances.15,22,65 A
favorable immune response involves alternatively-ac-
tivated (M2) macrophages, which contribute to anti-
inﬂammatory, angiogenic and tissue remodeling
responses. Conversely, the classically-activated (M1)
macrophages have been linked to inﬂammation, tissue
destruction, microbial destruction and clearance of
apoptotic cells.22 There is limited information on the
immunological responses following uterine tissue
engineering transplantations, and these important is-
sues need to be addressed. Especially, since one of the
key objectives is to develop an optimal patient-speciﬁc
grafting material to avoid the use of immunosuppres-
sive drugs. However, a temporary immunosuppressive
treatment-regime may be favorable to suppress a pos-
sible detrimental M1-related immune response, and to
instead potentiate a beneﬁcial M2-related stimulus
after transplantation. Indeed, a higher ratio of M2
macrophages vs. M1 macrophages was associated with
better transplantation and remodeling outcomes of
other non-uterus related decellularized materials in a
rat model.17 Transplanted BM-MSCs have been sug-
gested to act in an immune modulating manner
through paracrine actions in many systems,52,56,65
including the uterus20,21 and therefore seem to have an
important role to play in tissue engineering.
The choice of cells used for the recellularization
process plays a major role in the outcome of the tissue
reconstruction. We believe that it is likely that a mix of
various cell types, including endothelial cells, will be
required to reconstruct a functional uterine tissue from
decellularized tissues. Uterus side population
cells19,21,72 or endometrial mesenchymal stem/stromal
cells26,37,99 have shown somatic uterine stem cell
characteristics and an ability to reconstruct uterine
tissue. These cells may therefore be suitable cell sources
for uterine tissue engineering applications. However,
for women who completely lack uterine tissue, other
autologous cells sources such as BM-MSCs and/or IPS
cells should be explored.
CONCLUDING REMARKS AND HURDLES
TO OVERCOME
Great progress has been made in the last decade in
regenerative medicine, including how to bioengineer
Uterine Tissue Engineering
uterine tissues. Several promising scaﬀold designs have
been established but a major limitation is the in vitro
and in vivo recellularization efﬁciency. This matter may
be caused by an insufﬁcient scaffold homeostasis and/
or by inadequate in vitro 3D culturing conditions,
which can affect the balance between hypoxia, repop-
ulation and re-vascularization of the construct. The
outcome from these factors may also be cell type-de-
pendent; hence, more studies focusing on the culturing
conditions and the various cell sources, including
uterine- and endothelial-associated cell types, IPS-cells,
and/or various somatic stem cells added in a speciﬁc
sequence during the reconstruction process should be
explored in future research. However, vast expansion
of pluripotent cells may lead to undesirable phenotypic
changes which also need to be considered. The immune
response following engineered uterine tissue trans-
plantation should also be deeper investigated since it
plays a signiﬁcant role in the regeneration- or the
destruction of the grafts. However, the construction of
bioengineered uterine patches, which may be clinically
applied to repair a partial defect in the uterine wall,
have come a long way and it may be time to move
forward and evaluate some of these constructs in larger
animal models. Results from such experiments would
certainly contribute to our understanding on how to
construct a whole bioengineered uterus that can re-
place a donor in a UTx setting, which still is in its
initial stages of development.
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